​

Nautilus Bio Stock (NASDAQ:NAUT)

ForecastRevenueOwnershipFinancialsChartTranscripts
Nautilus Bio by TradingView

Previous Close

$2.43

52W Range

$0.62 - $3.08

50D Avg

$2.23

200D Avg

$1.38

Market Cap

$306.28M

Avg Vol (3M)

$215.27K

Beta

1.36

Div Yield

-

NAUT Company Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

134

IPO Date

Aug 07, 2020

Website

NAUT Performance

NAUT Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-81.48M$-76.15M
Net Income$-59.00M$-70.78M$-63.67M
EBITDA-$-64.43M$-74.30M
Basic EPS$-0.47$-0.56$-0.51
Diluted EPS$-0.47$-0.56$-0.51

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 26, 26 | 8:30 AM
Q3 25Oct 28, 25 | 8:30 AM
Q2 25Aug 01, 25 | 8:30 AM

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
ARCTArcturus Therapeutics Holdings Inc.
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
HUMAHumacyte, Inc.
ASMBAssembly Biosciences, Inc.
SGMTSagimet Biosciences Inc.
IMRXImmuneering Corporation
ZURAZura Bio Limited